Zacks Investment Research
12 Jun 2026, 23:16 UTC · 2h ago
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
12 Jun 2026, 23:16 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Pacific Biosciences of California (PACB) currently holds a Zacks Rank of #2 (Buy). — A 'Buy' rating from a quantitative ranking system typically signals a positive outlook for the stock's near-term performance.
+0.40The Zacks Consensus EPS estimate for PACB has increased by 7.41% over the past month. — Upward revisions in earnings estimates generally correlate with improved investor sentiment and price appreciation.
+0.30PACB is projected to report an EPS of -$0.14 for the upcoming quarter, representing a 7.69% decline year-over-year. — Declining earnings per share suggest weakening profitability or increasing costs for the company.
-0.20Continue reading
6 related stories
Top 2 movers · tap to explore
Consensus revenue estimates for PACB's upcoming quarter are $42.1 million, a 5.86% increase over the prior year. — Slight revenue growth indicates a positive trend in top-line demand, though it is modest.
Which stocks this story touches
The stock price fell recently and is predicted to post a decline in EPS compared to the equivalent quarter last year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3h ago
